Status:
ACTIVE_NOT_RECRUITING
A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practic...
Eligibility Criteria
Inclusion
- Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the European Union
- The decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study
- Patient is at least 18 years of age at the time of treatment decision
- Patient provided written informed consent to participate in the study
Exclusion
- Any contraindications according to the approved deucravacitinib Summary of Product Characteristics
- Prior treatment with deucravacitinib
- Simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis
Key Trial Info
Start Date :
April 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2030
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT06104644
Start Date
April 13 2023
End Date
May 31 2030
Last Update
December 4 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatologische Spezial- und Schwerpunktpraxis Selters
Selters, Rhineland-Palatinate, Germany
2
Local Institution - 0001
Selters, Germany, 56242